495 related articles for article (PubMed ID: 35337058)
21. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
22. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
Front Immunol; 2022; 13():907615. PubMed ID: 35812459
[TBL] [Abstract][Full Text] [Related]
23. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
24. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
Viruses; 2022 May; 14(5):. PubMed ID: 35632698
[TBL] [Abstract][Full Text] [Related]
25. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
[TBL] [Abstract][Full Text] [Related]
26. BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?
Darwich A; Pozzi C; Fornasa G; Lizier M; Azzolini E; Spadoni I; Carli F; Voza A; Desai A; Ferrero C; Germagnoli L; ; Mantovani A; Rescigno M
EMBO Mol Med; 2022 May; 14(5):e15326. PubMed ID: 35393790
[TBL] [Abstract][Full Text] [Related]
27. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.
Tyner HL; Burgess JL; Grant L; Gaglani M; Kuntz JL; Naleway AL; Thornburg NJ; Caban-Martinez AJ; Yoon SK; Herring MK; Beitel SC; Blanton L; Nikolich-Zugich J; Thiese MS; Pleasants JF; Fowlkes AL; Lutrick K; Dunnigan K; Yoo YM; Rose S; Groom H; Meece J; Wesley MG; Schaefer-Solle N; Louzado-Feliciano P; Edwards LJ; Olsho LEW; Thompson MG
Clin Infect Dis; 2022 Aug; 75(1):e827-e837. PubMed ID: 34928334
[TBL] [Abstract][Full Text] [Related]
29. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
31. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
32. MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.
Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Rivera Ballesteros O; Muvva JR; ; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren HG; Aleman S; Sandberg JK
Mol Med; 2022 May; 28(1):54. PubMed ID: 35562666
[TBL] [Abstract][Full Text] [Related]
33. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
34. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
35. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
36. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL
Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782
[TBL] [Abstract][Full Text] [Related]
37. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
38. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women.
Yeo KT; Chia WN; Tan CW; Ong C; Yeo JG; Zhang J; Poh SL; Lim AJM; Sim KHZ; Sutamam N; Chua CJH; Albani S; Wang LF; Chua MC
Front Immunol; 2021; 12():783975. PubMed ID: 35087517
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
